May 26, 2023
Sumitomo Pharma has submitted a clinical trial notification in Japan to commence a PI/II study for its cell therapy HLCR011 being codeveloped with Healios for the treatment of retinal pigment epithelial (RPE) tears, the companies said on May 25. HLCR011...read more